drugset / Trial / NCT06106152
WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody
Phase 0
Unknown
20 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Westlake Therapeutics · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This trial is a single-center, open-label designed investigator-initiated clinical study (IIT) to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of WTX212A injection WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with advanced lung cancer
Timeline
- Start
- 2023-12-05
- Primary completion
- 2024-10-30
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | WTX212A | Protein / enzyme biologic | — | Other |